Recherche
-
Impact of the COVID-19 pandemic and its control measures on cardiovascular and antidiabetic drugs use in France in 2020: a nationwide repeated cohort study
(European Journal of Epidemiology. pp. 1-11, 2022-09-21)Article de revue -
Use of cardiovascular and antidiabetic drugs during COVID19 epidemic in France
(Fundamental & Clinical Pharmacology. vol. 36, n° S1, pp. 94-95, 2022-06)Article de revue -
Myocardial infarction associated with erenumab: a case report.
(PHARMACOTHERAPY, 2022-05-27)Article de revueLibre accès -
High-Dimensional Propensity Score-Adjusted Case-Crossover for Discovering Adverse Drug Reactions from Computerized Administrative Healthcare Databases
(Drug Safety, 2022-02-18)Article de revue -
A meta-epidemiological study found lack of transparency and poor reporting of disproportionality analyses for signal detection in pharmacovigilance databases
(Journal of Clinical Epidemiology, 2021-07-27)Article de revue -
Risk of first ischemic stroke and use of antidopaminergic antiemetics: A nationwide case-time-control study
(Fundamental and Clinical Pharmacology. vol. 36, pp. 22-23, 2022-06)Article de revue -
Risk of first ischaemic stroke and use of antidopaminergic antiemetics: nationwide case-time-control study
(BMJ. vol. 376, 2022-03-23)Article de revueLibre accès -
Spontaneous Reports of Serious Adverse Drug Reactions Resulting From Drug–Drug Interactions: An Analysis From the French Pharmacovigilance Database
(Frontiers in Pharmacology. vol. 11, pp. 624562, 2021-03-24)Article de revueLibre accès -
General practitioners' compliance with benzodiazepine discontinuation guidelines in patients treated with long-term lorazepam: A case-vignette cross-sectional survey
(Thérapie, 2021-09-16)Article de revue -
The risk of dementia in patients using psychotropic drugs: Antidepressants, mood stabilizers or antipsychotics
(Acta Psychiatrica Scandinavica. vol. 145, n° 1, pp. 56-66, 2022-01)Article de revue